“Cancer research funding cuts” has meant several different things since early 2025, and by mid-2026 the gap between what was proposed for the National Cancer Institute (NCI) and what actually reached cancer labs is wide enough that a single headline figure is misleading either way. This piece is specifically about NCI and cancer-research funding — for the broader NIH-wide appropriations, grant-termination litigation, and indirect-cost story, see CASRAI’s companion piece, NIH funding cuts in 2026: what actually happened, which this post assumes as background and does not repeat in full.
The proposed cut: NCI’s FY2026 budget request
The administration’s FY2026 budget request sought a roughly 37–43% reduction to NCI’s appropriated budget relative to FY2025 — reporting converges on the direction and rough magnitude but not on a single precise figure: some coverage puts the request at a $2.69 billion cut (from $7.22 billion to roughly $4.53 billion, about 37%), while other coverage cites a steeper reduction to around $4.1 billion (about 43%) (Becker’s Hospital Review; ASCO). Either figure would have been the largest single-year cut to NCI’s budget in the agency’s history. The same request proposed consolidating NIH’s 27 institutes and centers — including NCI — into a smaller set of umbrella entities, a structural change separate from the dollar figure.
What Congress actually enacted
Congress rejected the administration’s proposed downsizing at the NIH-wide level: the spending bill signed February 3, 2026 funded NIH overall at $48.7 billion for FY2026, a roughly 0.9% increase over FY2025, and left NIH’s 27-institute structure intact (STAT News). What the publicly reported topline numbers do not settle is whether NCI’s own line-item appropriation within that bill tracked the flat-to-slightly-up NIH-wide outcome exactly, or came in lower or higher than that average — institute-by-institute breakdowns of the enacted bill were not consistently reported alongside the topline figure, and CASRAI has not independently confirmed NCI’s specific FY2026 line item against the enacted appropriations text. Treat “NCI’s budget was cut 40%” as describing the proposal, not a confirmed enacted outcome, and treat “cancer research funding is fine because NIH overall went up slightly” with the same caution — both oversimplify what is, at the institute level, a genuinely unsettled or at least under-reported number.
The reduction that is real regardless: below-full-value funding of new awards
Separately from the appropriations-line question above, NCI has a documented recent pattern of funding new and competing grants below the budget level its own study sections and Institute and Center Review Groups (IRGs) recommended — a practice distinct from, and layered on top of, whatever NCI’s topline appropriation turns out to be. CASRAI’s NCI Funding guide already documents this trend through FY2025: an 8th-percentile R01 payline in FY2019 rising toward a stated 15th-percentile goal, back down to 10th percentile by FY2024, and no single published FY2025 R01 payline at all — NCI instead funded applications in percentile order as its budget allowed. For FY2026, secondary reporting describes NCI applying specific percentage reductions to new award budgets rather than publishing one payline number: figures reported include roughly a 6.5–8.5% reduction on new R01 budgets depending on direct-cost size, and steeper reductions (reportedly in the 13–17% range) on larger R01s and on P01/UM1/R33 mechanisms (OncologyTube, aggregating NCI’s own funding-policy notices). NCI’s primary funding-policy page (grants.nih.gov’s NCI-specific fiscal policy page) returned an access error on direct retrieval this session, so treat these specific percentages as reported rather than independently confirmed against NCI’s own notice text — the direction (awards funded below what peer review recommended) is well corroborated across multiple sources, the exact percentages are the part worth re-checking against NCI’s own Bottom Line Blog before treating a specific figure as current for a specific grant.
Reported downstream effects
Beyond the budget mechanics, cancer-research-specific outlets and organizations have reported concrete operational consequences through 2025 into 2026: KFF Health News described disruption inside NCI itself, including staff departures and reorganized offices (KFF Health News); the Association of American Cancer Institutes and ASCO both raised concerns specifically about capacity for new clinical trials, retention of trained research staff whose funding lapsed, and the compounding effect of the (separately litigated) 15% indirect-cost cap proposal on cancer centers’ ability to cover the actual cost of running trials. These are reported concerns and described early effects from advocacy and news organizations, not independently audited outcome data CASRAI has verified directly — cite them as “reported by X,” not as settled fact, when using this page as a source.
What this means for cancer-research grant administrators
- Don’t conflate the proposal with the appropriation. The 37–43% figure describes a budget request Congress did not enact at the NIH-wide level; whether NCI specifically saw a comparable increase, a smaller one, or a cut within the enacted bill is not settled by the topline number alone.
- Budget new NCI awards below the study-section-recommended amount. Regardless of how the appropriations line lands, the pattern of funding new/competing awards below IRG-recommended levels has held for several consecutive fiscal years and is reported to continue into FY2026 — a PI’s Notice of Award amount below what the summary statement suggested is not necessarily an error.
- Track NCI’s own notices, not just news coverage, for a specific grant’s number. The percentage reductions above vary by mechanism and direct-cost size and change during the fiscal year; the NCI Bottom Line Blog and NCI’s own funding-policy notices are the primary source to check before finalizing a subaward or hiring plan against an anticipated award amount.
- Keep this separate from the broader NIH litigation and indirect-cost stories. The APHA v. NIH grant-termination litigation and NOT-OD-26-072’s subaward-threshold rollback, covered in CASRAI’s NIH funding cuts in 2026 piece, apply NIH-wide and are not specific to cancer research, though they compound the same institutions’ budget pressure.
Frequently asked questions
Did Congress cut the National Cancer Institute’s budget by 40% in 2026?
No, not as an enacted, confirmed outcome. A roughly 37–43% cut to NCI was what the administration’s FY2026 budget request proposed. Congress rejected the administration’s proposed NIH-wide downsizing and instead funded NIH overall at $48.7 billion for FY2026, a small increase over FY2025. Institute-by-institute figures within that enacted bill, including NCI’s specific line item, are not consistently reported publicly, so a precise enacted NCI number is not something this page can confirm.
If NIH’s overall budget went up, why are cancer researchers still describing funding cuts?
Two different things are true at once. NIH’s topline appropriation was flat to slightly up. Separately, NCI has continued a multi-year pattern of funding new and competing grant awards below what peer review recommended — a below-full-value reduction applied at the award level, reported to continue in FY2026, that a flat or growing topline budget number does not capture or prevent.
Is this the same story as the “NIH funding cuts” news covered elsewhere on CASRAI?
It overlaps but is not the same. CASRAI’s NIH-wide funding cuts piece covers the general appropriations fight, the APHA v. NIH grant-termination litigation, and the NOT-OD-26-072 indirect-cost notice — all NIH-wide, not cancer-specific. This page focuses on what’s specific to NCI and cancer research: the proposed-vs-enacted budget gap and the below-IRG-recommendation funding pattern for cancer grants.
Where can a research administrator verify a specific cancer-grant funding percentage?
Directly against NCI’s own current-year notices — the NCI Bottom Line Blog and the NCI-specific funding policy page at grants.nih.gov are the primary sources, since the exact reduction percentage varies by grant mechanism, direct-cost size, and changes during the fiscal year as NCI’s actual appropriation firms up.
Related: Cancer Research Funding: A Landscape Overview, NCI Funding, NIH payline, NIH 15% indirect cost cap.
